论文部分内容阅读
目的比较布地奈德福莫特罗与孟鲁司特治疗支气管哮喘的疗效。方法 198例接受治疗的支气管哮喘患者,按照随机数字表法随机分为A组与B组,各99例。观察两组患者一秒用力呼气容积(FEV1)、FEV1/FVC、峰流速(PEF)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、TNF-α及临床疗效。结果两组患者治疗后FEV1、FEV1/FVC、PEF、IL-6、IL-8、IL-10、TNF-α等指标均显著优于治疗前(P<0.05),A组患者治疗后FEV1、FEV1/FVC、PEF、IL-6、IL-8、IL-10、TNF-α等指标优于B组,但差异无统计学意义(P>0.05)。A组治疗总有效率(96.97%)优于B组(92.93%),差异无统计学意义(P>0.05)。结论布地奈德福莫特罗与孟鲁司特治疗支气管哮喘疗效无显著差异,均可应用于支气管哮喘的临床治疗。
Objective To compare the efficacy of budesonide formoterol and montelukast in the treatment of bronchial asthma. Methods A total of 198 patients with bronchial asthma who were treated were randomly divided into A group and B group according to the random number table method, each with 99 cases. The forced expiratory volume in one second, FEV1 / FVC, PEF, IL-6, IL-8 and IL- 10 (IL-10), TNF-α and clinical efficacy. Results The FEV1, FEV1 / FVC, PEF, IL-6, IL-8, IL-10 and TNF-α in the two groups were significantly better than those before treatment (P < The indexes such as FEV1 / FVC, PEF, IL-6, IL-8, IL-10 and TNF-αwere better than those in group B, but the difference was not statistically significant (P> 0.05). The total effective rate in group A (96.97%) was better than that in group B (92.93%), with no significant difference (P> 0.05). Conclusions The efficacy of budesonide formoterol and montelukast in the treatment of bronchial asthma has no significant difference and can be used in the clinical treatment of bronchial asthma.